298 related articles for article (PubMed ID: 29537104)
1. Aligning physics and physiology: Engineering antibodies for radionuclide delivery.
Tsai WK; Wu AM
J Labelled Comp Radiopharm; 2018 Jul; 61(9):693-714. PubMed ID: 29537104
[TBL] [Abstract][Full Text] [Related]
2. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
3. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
4. Targeted Radioimmunotherapy and Theranostics with Alpha Emitters.
Pandit-Taskar N
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S41-S44. PubMed ID: 31451417
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based Radiopharmaceuticals as Theranostic Agents: An Overview.
Sharma R; Suman SK; Mukherjee A
Curr Med Chem; 2022; 29(38):5979-6005. PubMed ID: 35674298
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunodetection and therapy of breast cancer.
DeNardo SJ
Semin Nucl Med; 2005 Apr; 35(2):143-51. PubMed ID: 15765377
[TBL] [Abstract][Full Text] [Related]
7. Protein targeting constructs in alpha therapy.
Olafsen T; Elgqvist J; Wu AM
Curr Radiopharm; 2011 Jul; 4(3):197-213. PubMed ID: 22201709
[TBL] [Abstract][Full Text] [Related]
8. Radionuclide therapy of cancer with radiolabeled antibodies.
Boerman OC; Koppe MJ; Postema EJ; Corstens FH; Oyen WJ
Anticancer Agents Med Chem; 2007 May; 7(3):335-43. PubMed ID: 17504159
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy with engineered antibodies.
Russeva MG; Adams GP
Expert Opin Biol Ther; 2004 Feb; 4(2):217-31. PubMed ID: 14998779
[TBL] [Abstract][Full Text] [Related]
10. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.
Orcutt KD; Slusarczyk AL; Cieslewicz M; Ruiz-Yi B; Bhushan KR; Frangioni JV; Wittrup KD
Nucl Med Biol; 2011 Feb; 38(2):223-33. PubMed ID: 21315278
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges.
Martins CD; Kramer-Marek G; Oyen WJG
Expert Opin Drug Deliv; 2018 Feb; 15(2):185-196. PubMed ID: 28893110
[TBL] [Abstract][Full Text] [Related]
12. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
13. Tailoring antibodies for radionuclide delivery.
Kenanova V; Wu AM
Expert Opin Drug Deliv; 2006 Jan; 3(1):53-70. PubMed ID: 16370940
[TBL] [Abstract][Full Text] [Related]
14. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.
Knowles SM; Wu AM
J Clin Oncol; 2012 Nov; 30(31):3884-92. PubMed ID: 22987087
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic radionuclides: production and decay property considerations.
Volkert WA; Goeckeler WF; Ehrhardt GJ; Ketring AR
J Nucl Med; 1991 Jan; 32(1):174-85. PubMed ID: 1988628
[TBL] [Abstract][Full Text] [Related]
16. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy.
Srivastava SC
Cancer Biother Radiopharm; 1996 Feb; 11(1):43-50. PubMed ID: 10851519
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
18. Centralized radiolabeling of antibodies for radioimmunotherapy.
Colcher D
J Nucl Med; 1998 Aug; 39(8 Suppl):11S-13S. PubMed ID: 9708565
[TBL] [Abstract][Full Text] [Related]
19. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
20. Improvement of radioimmunotherapy using pretargeting.
Frampas E; Rousseau C; Bodet-Milin C; Barbet J; Chatal JF; Kraeber-Bodéré F
Front Oncol; 2013; 3():159. PubMed ID: 23802097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
